Cumberland Pharmaceuticals (CPIX) Net Cash Flow (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Net Cash Flow of -$437448.0 for Q1 2026, up 84.68% on a YoY basis from -$236865.6 in Q1 2025, and up 88.34% sequentially from -$3.8 million in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Net Cash Flow (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 17 years of Net Cash Flow data on file, last reported at -$437448.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 84.68% year-over-year to -$437448.0; the trailing twelve-month figure through Mar 2026 stood at -$4.1 million (down 19.22% YoY), and the FY2025 full-year result was -$6.5 million, down 1723.94% from the prior year.
- Net Cash Flow grew to -$437448.0 in Q1 2026, from -$3.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.9 million in Q2 2023 to a low of -$9.8 million in Q1 2022.
- A 5-year average of -$943151.2 and a median of $128308.0 in 2024 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow slumped 5879.04% in 2022 and surged 368.02% in 2024, its largest moves.
- Tracing CPIX's Net Cash Flow over 5 years: stood at $216432.0 in 2022, then tumbled by 186.1% to -$186341.0 in 2023, then surged by 368.02% to $499430.0 in 2024, then sank by 851.27% to -$3.8 million in 2025, then soared by 88.34% to -$437448.0 in 2026.
- Business Quant data shows CPIX's Net Cash Flow at -$437448.0 in Q1 2026, -$3.8 million in Q4 2025, and -$890536.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn | -437,448.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -437,448.00 |
| Mar 31, 2026 | -437,448.00 |
| Dec 31, 2025 | -3.75 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Sep 30, 2025 | -890,536.00 |
| Sep 30, 2025 | -890,536.00 |
| Jun 30, 2025 | 978,868.00 |
| Jun 30, 2025 | 978,868.00 |
| Mar 31, 2025 | -2.86 Mn |
| Mar 31, 2025 | -2.86 Mn |
| Dec 31, 2024 | 499,430.00 |
| Dec 31, 2024 | 499,430.00 |
| Sep 30, 2024 | 128,308.00 |
| Sep 30, 2024 | 128,308.00 |
| Jun 30, 2024 | -1.21 Mn |
| Jun 30, 2024 | -1.21 Mn |
| Mar 31, 2024 | 226,861.00 |
| Mar 31, 2024 | 226,861.00 |
| Dec 31, 2023 | -186,341.00 |
| Dec 31, 2023 | -186,341.00 |